November 03, 2020
SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) has announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering price of US$16.00 per share. All of the shares of common stock are being offered by SQZ. In addition, SQZ has granted the underwriters a 30-day option to purchase up to an additional 661,764 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. SQZ’s common stock trades on the New York Stock Exchange under the ticker symbol “SQZ.”
Latham & Watkins LLP represented SQZ Biotechnologies Company in the transaction with a capital markets deal team led by partners Peter Handrinos and Wesley Holmes, with associates Jennifer Yoon, N. Danny Shulman, and Michael Casagrande. Advice was also provided on benefits and compensation matters by partner Matthew Conway, with associate Kirk Porter; on technology transactions matters by partner Alan Tamarelli, with associate Seth Appiah-Opoku; on FDA regulatory matters by partner Ben Haas and counsel Betty Pang, with associates Chad Jennings, Barrett Tenbarge, and Kiera Murphy; on tax matters by partner Jocelyn Noll, with associate Michael Yu; and on other corporate matters by partner Jenna Cooper, with associate Justin McNamee.